| Subtyping of triple‐negative breast cancer: implications for therapy VG Abramson, BD Lehmann, TJ Ballinger, JA Pietenpol Cancer 121 (1), 8-16, 2015 | 424 | 2015 |
| TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes NM Tung, ME Robson, S Ventz, CA Santa-Maria, R Nanda, PK Marcom, ... Journal of Clinical Oncology 38 (36), 4274-4282, 2020 | 382 | 2020 |
| Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer … M Radovich, G Jiang, BA Hancock, C Chitambar, R Nanda, C Falkson, ... JAMA oncology 6 (9), 1410-1415, 2020 | 236 | 2020 |
| Efficacy of circulating tumor cell count–driven vs clinician-driven first-line therapy choice in hormone receptor–positive, ERBB2-negative metastatic breast cancer: The STIC … FC Bidard, W Jacot, N Kiavue, S Dureau, A Kadi, E Brain, T Bachelot, ... JAMA oncology 7 (1), 34-41, 2021 | 145 | 2021 |
| Current landscape of targeted therapies for hormone-receptor positive, HER2 negative metastatic breast cancer TJ Ballinger, JB Meier, VM Jansen Frontiers in oncology 8, 308, 2018 | 81 | 2018 |
| TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib … NM Tung, ME Robson, S Ventz, CA Santa-Maria, PK Marcom, R Nanda, ... Journal of Clinical Oncology 38 (15_suppl), 1002-1002, 2020 | 61 | 2020 |
| Current HER2 testing recommendations and clinical relevance as a predictor of response to targeted therapy TJ Ballinger, ME Sanders, VG Abramson Clinical breast cancer 15 (3), 171-180, 2015 | 55 | 2015 |
| Inhibiting fatty acid synthase with omeprazole to improve efficacy of neoadjuvant chemotherapy in patients with operable TNBC SD Sardesai, A Thomas, C Gallagher, F Lynce, YL Ottaviano, TJ Ballinger, ... Clinical Cancer Research 27 (21), 5810-5817, 2021 | 33 | 2021 |
| BRE12-158: a postneoadjuvant, randomized phase II trial of personalized therapy versus treatment of physician's choice for patients with residual triple-negative breast cancer BP Schneider, G Jiang, TJ Ballinger, F Shen, C Chitambar, R Nanda, ... Journal of Clinical Oncology 40 (4), 345-355, 2022 | 32 | 2022 |
| Association of Allostatic Load With All-Cause Mortality in Patients With Breast Cancer S Obeng-Gyasi, MI Elsaid, Y Lu, JC Chen, WE Carson, TJ Ballinger, ... JAMA Network Open 6 (5), e2313989-e2313989, 2023 | 29 | 2023 |
| Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors VG Abramson, JG Supko, T Ballinger, JM Cleary, JF Hilton, SM Tolaney, ... Clinical Cancer Research 23 (14), 3520-3528, 2017 | 27 | 2017 |
| Patient preferences regarding chemotherapy in metastatic breast cancer—a conjoint analysis for common taxanes S Spaich, J Kinder, S Hetjens, S Fuxius, A Gerhardt, M Sütterlin Frontiers in oncology 8, 535, 2018 | 26 | 2018 |
| NCCN Guidelines® Insights: Survivorship, Version 1.2022: Featured Updates to the NCCN Guidelines T Sanft, A Day, L Peterson, MA Rodriguez, S Ansbaugh, S Armenian, ... Journal of the National Comprehensive Cancer Network 20 (10), 1080-1090, 2022 | 25 | 2022 |
| How we manage JAK inhibition in allogeneic transplantation for myelofibrosis TJ Ballinger, BN Savani, V Gupta, N Kroger, M Mohty European Journal of Haematology 94 (2), 115-119, 2015 | 24 | 2015 |
| Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling VG Abramson, M Cooper Lloyd, T Ballinger, ME Sanders, L Du, D Lai, ... Breast cancer research and treatment 145, 389-399, 2014 | 24 | 2014 |
| Triple negative breast cancer-Review of current and emerging therapeutic strategies T Ballinger, J Kremer, K Miller | 22 | 2016 |
| Impact of primary breast cancer therapy on energetic capacity and body composition TJ Ballinger, A Reddy, SK Althouse, EM Nelson, KD Miller, JS Sledge Breast cancer research and treatment 172, 445-452, 2018 | 21 | 2018 |
| Imaging modalities for measuring body composition in patients with cancer: opportunities and challenges UA Shah, TJ Ballinger, R Bhandari, CM Dieli-Conwright, KA Guertin, ... JNCI Monographs 2023 (61), 56-67, 2023 | 17 | 2023 |
| Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer M Radovich, JP Solzak, CJ Wang, BA Hancock, S Badve, SK Althouse, ... Clinical Cancer Research 28 (15), 3235-3241, 2022 | 14 | 2022 |
| NKG2A is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple Negative Breast Cancer BC Taylor, X Sun, PI Gonzalez-Ericsson, V Sanchez, ME Sanders, ... Cancer Discovery, 2023 | 13 | 2023 |
